Emory psychiatrist steps down

Written byBob Grant

| 2 min read

Renowned psychiatrist Charles Nemeroff stepped down from his position as chairman of the psychiatry department at Emory University on Friday (Oct. 3) amid accusations that he's failed to disclose hundreds of thousands of dollars in pharmaceutical company payouts while receiving millions of dollars in federal research funding. Nemeroff's apparent lack of disclosure is being probed by Senator linkurl:Charles Grassley;http://www.the-scientist.com/blog/display/54832/ (R-IA) from his perch as the ranking Republican in the Senate Finance Committee. Following the psychiatrist's departure, Emory University officials told the linkurl:__Atlanta Journal-Constitution__;http://www.ajc.com/metro/content/metro/dekalb/stories/2008/10/04/Emory_professor_investigation.html over the weekend that the school is launching its own investigation into Nemeroff's activities. In a linkurl:letter;http://frwebgate6.access.gpo.gov/cgi-bin/PDFgate.cgi?WAISdocID=310197337729+0+1+0&WAISaction=retrieve sent to Emory president James Wagner last week, Grassley outlined discrepancies in Nemeroff's disclosure reports to the university. From 2003 - 2008, as Nemeroff served as principal investigator on a multi-million dollar grant from the National Institutes of Health to study five GlaxoSmithKline (GSK) antidepressants, the psychiatrist was paid - and failed to report to Emory - more than $100,000 to give promotional talks on the company's products. Grassley wrote that "in 2003 GSK paid Dr. Nemeroff about $119,000 in speaking fees and expenses. Based upon information provided from Emory, Dr. Nemeroff did not report that he was giving promotional talks for GSK on Paxil and Lamictal." Grassley also pointed out that in 2004, Emory's own conflict of interest committee reprimanded Nemeroff for failing to report earnings from GSK. Emory and NIH policies state that researchers must report potentially conflicting financial ties to industry that total $10,000 per year or more. Nemeroff told the committee that he would adhere to the policy in the future, wrote Grassley. Shortly after making this promise, however, Nemeroff was back on the promotional circuit for GSK, giving two talks for the company for a fee greater than $10,000, according to Grassley's letter. In 2006, Nemeroff linkurl:quit;http://www.the-scientist.com/news/display/24445/ as the editor-in-chief of __Neuropsychopharmacology__ after coming under fire for failing to disclose financial ties to a device company whose products he reviewed favorably in the journal. Before that, in 2003, Nemeroff and an Emory colleague linkurl:took heat;http://www.the-scientist.com/article/display/21640/ for publishing a paper in __Nature Neuroscience__ that praised a trio of products to treat mood disorders, while failing to mention that the two had significant financial stakes in the products. "There were serious allegations in the past, and now there are even more allegations. And we are investigating," Emory University executive vice president of academic affairs, Earl Lewis, told the Atlanta Journal-Constitution. Lewis also told the __AJC__ that Nemeroff could be fired from Emory depending on the outcome of the university's investigation. Check out a detailed timeline of Nemeroff's alleged indiscretions over at the linkurl:Pharmalot;http://www.pharmalot.com/2008/10/emory-fiddled-while-nemeroff-earned/ blog.

Meet the Author

Bob Grant

From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

View Full Profile

Emory psychiatrist steps down

The Scientist ARCHIVES

Become a Member of

Meet the Author

Bob Grant

Related Research Resources

A Stubborn Gene, a Failed Experiment, and a New Path

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies